WO1999053917A1 - Cannabinoids as antioxidants and neuroprotectants - Google Patents
Cannabinoids as antioxidants and neuroprotectants Download PDFInfo
- Publication number
- WO1999053917A1 WO1999053917A1 PCT/US1999/008769 US9908769W WO9953917A1 WO 1999053917 A1 WO1999053917 A1 WO 1999053917A1 US 9908769 W US9908769 W US 9908769W WO 9953917 A1 WO9953917 A1 WO 9953917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cannabinoid
- group
- disease
- lipoxygenase
- cannabinoids
- Prior art date
Links
- 0 CCc1c(*)c(*)cc(*)c1* Chemical compound CCc1c(*)c(*)cc(*)c1* 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38646/99A AU766988B2 (en) | 1998-04-21 | 1999-04-21 | Cannabinoids as antioxidants and neuroprotectants |
US09/674,028 US6630507B1 (en) | 1998-04-21 | 1999-04-21 | Cannabinoids as antioxidants and neuroprotectants |
CA002329626A CA2329626A1 (en) | 1998-04-21 | 1999-04-21 | Cannabinoids as antioxidants and neuroprotectants |
DE69936640T DE69936640D1 (en) | 1998-04-21 | 1999-04-21 | CANNABINOIDS AS ANTIOXIDANTS AND NEUROSHIPPING AGENTS |
JP2000544322A JP2002512188A (en) | 1998-04-21 | 1999-04-21 | Cannabinoids as antioxidants and neuroprotective agents |
EP99921427A EP1071419B1 (en) | 1998-04-21 | 1999-04-21 | Cannabinoids as antioxidants and neuroprotectants |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8258998P | 1998-04-21 | 1998-04-21 | |
US9599398P | 1998-08-10 | 1998-08-10 | |
US60/082,589 | 1998-08-10 | ||
US60/095,993 | 1998-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999053917A1 true WO1999053917A1 (en) | 1999-10-28 |
Family
ID=26767641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/008769 WO1999053917A1 (en) | 1998-04-21 | 1999-04-21 | Cannabinoids as antioxidants and neuroprotectants |
Country Status (8)
Country | Link |
---|---|
US (1) | US6630507B1 (en) |
EP (1) | EP1071419B1 (en) |
JP (1) | JP2002512188A (en) |
AT (1) | ATE367809T1 (en) |
AU (1) | AU766988B2 (en) |
CA (1) | CA2329626A1 (en) |
DE (1) | DE69936640D1 (en) |
WO (1) | WO1999053917A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000056303A2 (en) * | 1999-03-22 | 2000-09-28 | Immugen Pharmaceuticals, Inc. | Treatment of immune diseases |
WO2001003690A1 (en) * | 1999-07-12 | 2001-01-18 | Virginia Commonwealth University | Novel vasodilator cannabinoid analogs |
WO2002064169A1 (en) * | 2001-02-16 | 2002-08-22 | Daiichi Suntory Pharma Co., Ltd. | Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases |
WO2003015700A2 (en) * | 2001-08-15 | 2003-02-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Novel vasoconstrictor cannabinoid analogs |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US6630507B1 (en) * | 1998-04-21 | 2003-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
WO2004105699A2 (en) * | 2003-05-28 | 2004-12-09 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage |
WO2005077348A1 (en) * | 2004-02-16 | 2005-08-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treating or preventing diabetes with cannabidiol |
WO2006024958A2 (en) * | 2004-08-09 | 2006-03-09 | Novimmune S.A. | Cannabinoid compositions and methods of use thereof |
WO2007105210A3 (en) * | 2006-03-13 | 2007-11-15 | Hadasit Med Res Service | Therapeutic uses of cannabidiol compounds |
WO2008107879A1 (en) * | 2007-03-05 | 2008-09-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel cannabidiol derivatives and their use as anti-inflammatory agents |
WO2009018389A1 (en) * | 2007-07-30 | 2009-02-05 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
EP2298284A3 (en) * | 2001-02-14 | 2013-12-18 | GW Pharma Limited | Mucoadhesive pharmaceutical formulations |
WO2014200350A1 (en) * | 2013-06-13 | 2014-12-18 | Cannabis Science International Holding B.V. | Composition for the treatment of neurobehavioral disorders |
US20160038437A1 (en) * | 2001-05-04 | 2016-02-11 | Gw Pharma Limited | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
EP3639814A1 (en) * | 2014-06-27 | 2020-04-22 | GW Research Limited | 7-oh-cannabidiol (7-oh-cbd) for use in the treatment of epilepsy |
WO2021007661A1 (en) * | 2019-07-12 | 2021-01-21 | Canopy Growth Corporation | Cannabinoid derivatives |
CN113735709A (en) * | 2021-09-17 | 2021-12-03 | 中国农业科学院农产品加工研究所 | Cannabidiol-2-butyrate and application thereof |
WO2021245671A1 (en) * | 2020-06-03 | 2021-12-09 | Epm (Ip), Inc. | Cannabidiolic acid (cbda) derivatives and uses thereof |
WO2022017957A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage |
WO2022113071A2 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid derivatives and their use the treatment of inflammation and/or pain and/or obesity |
WO2022238701A1 (en) * | 2021-05-12 | 2022-11-17 | GW Research Limited | Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof |
WO2022238707A1 (en) * | 2021-05-12 | 2022-11-17 | GW Research Limited | Rescorcinols, methods for their manufacture, and uses thereof |
WO2023285072A1 (en) | 2021-07-13 | 2023-01-19 | Receptorpharma Inc S-Corp | Esters of 7-cooh cbd derivatives and their use as prevention, prophylaxis of progression, and/or treatment of neurogenerative diseases. |
WO2023103734A1 (en) * | 2021-12-10 | 2023-06-15 | 德义制药有限公司 | Cannabidiol derivative, preparation method therefor and application thereof |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002326312A1 (en) * | 2002-04-25 | 2003-11-10 | Virginia Commonwealth University | Cannabinoids |
IL157849A0 (en) * | 2003-09-10 | 2004-03-28 | Yissum Res Dev Co | Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives |
US20060160748A1 (en) * | 2003-11-25 | 2006-07-20 | Shey-Shing Sheu | Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof |
JP4569142B2 (en) * | 2004-03-22 | 2010-10-27 | コニカミノルタホールディングス株式会社 | Display element |
KR20070118069A (en) * | 2004-12-09 | 2007-12-13 | 인시스 테라퓨틱스, 인코포레이티드 | Room-temperature stable dronabinol formulations |
US7597910B2 (en) * | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
WO2007041167A2 (en) * | 2005-09-29 | 2007-04-12 | Amr Technology, Inc. | Process for production of delta-9-tetrahydrocannabinol |
NZ573217A (en) | 2006-05-05 | 2011-11-25 | Plascoenergy Ip Holdings S L Bilbao Schaffhausen Branch | A facility for conversion of carbonaceous feedstock into a reformulated syngas containing CO and H2 |
GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
US20090318526A1 (en) * | 2006-06-08 | 2009-12-24 | Uno Jacob Weber | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
AU2007281918A1 (en) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
US9763894B2 (en) * | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
US8242178B2 (en) * | 2007-06-18 | 2012-08-14 | University Of South Carolina | Use of cannabidiol in the treatment of autoimmune hepatitis |
GB2451254A (en) * | 2007-07-24 | 2009-01-28 | Gw Pharma Ltd | Cannabidiol for use in the treatment of neurodegenerative conditions |
WO2009020666A1 (en) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
WO2010012506A1 (en) * | 2008-07-31 | 2010-02-04 | Bionorica Research Gmbh | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
US10105343B2 (en) | 2010-04-30 | 2018-10-23 | Kubby Patent And Licenses, Limited Liability Company | Cannabis based compositions and methods of treating hypertension |
KR101196354B1 (en) * | 2010-09-03 | 2012-11-01 | 서유헌 | Pharmaceutical composition for prevention or treatment of neurodegenerative brain diseases |
US8642645B2 (en) | 2011-05-20 | 2014-02-04 | Brooks Kelly Research, LLC. | Pharmaceutical composition comprising Cannabinoids |
US20150313868A1 (en) | 2012-12-18 | 2015-11-05 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
ES2649730T3 (en) * | 2013-03-15 | 2018-01-15 | Glia Llc | Cranial distribution of pharmaceutical compounds |
US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
MX2015013202A (en) | 2013-03-15 | 2016-04-07 | Biotech Inst Llc | Breeding, production, processing and use of specialty cannabis. |
US9095563B2 (en) | 2013-09-26 | 2015-08-04 | Ronald D. Sekura | Topical treatments incorporating Cannabis sp. derived botanical drug product |
CA3013907C (en) | 2013-10-29 | 2020-09-08 | Biotech Institute, Llc | Production and use of specialty cannabis with bd/bt genotype and a limonene-dominant terpene profile |
US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
EP3119391A4 (en) | 2014-03-18 | 2017-12-27 | Izun Pharmaceuticals Corp. | Protein-bound cannabinoid compositions |
WO2015200049A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US9822384B2 (en) | 2014-07-14 | 2017-11-21 | Librede Inc. | Production of cannabinoids in yeast |
US10897915B2 (en) | 2014-08-15 | 2021-01-26 | Blacklist Holdings, Inc. | Method for making coffee products containing cannabis ingredients |
US9565865B2 (en) | 2014-08-15 | 2017-02-14 | Imbue LLC | Method for making coffee products containing cannabis ingredients |
WO2016054268A1 (en) | 2014-09-30 | 2016-04-07 | MJAR Holdings, LLC | Methods of growing cannabaceae plants using artificial lighting |
GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
JP2017535539A (en) | 2014-10-21 | 2017-11-30 | ユナイテッド カナビス コーポレイション | Cannabis extract and its preparation and use |
US9539295B2 (en) | 2014-12-05 | 2017-01-10 | Bradley Michael Bohus | Cannabidiol (CBD) enriched alcohol |
WO2016105514A1 (en) | 2014-12-23 | 2016-06-30 | Biotech Institute, Llc | A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis |
MA41299A (en) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | OPHTHALMIC SOLUTIONS FOR THE TREATMENT OF GLAUCOMA AND CONJUNCTIVITIS |
CA3012599A1 (en) | 2015-01-26 | 2016-08-04 | Matthew W. Giese | Systems, apparatuses, and methods for classification |
US20160298151A1 (en) | 2015-04-09 | 2016-10-13 | Sher Ali Butt | Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products |
CA2986666A1 (en) | 2015-05-28 | 2016-12-01 | Tweed Inc. | Cannabis plants having modified expression of thca synthase |
AU2016337507B2 (en) * | 2015-10-16 | 2019-09-19 | Impact Biosciences Corp. | Methods and compositions for treating traumatic brain injury |
WO2017181118A1 (en) * | 2016-04-15 | 2017-10-19 | Full Spectrum Laboratories Ltd | Biosynthesis of cannabinoid prodrugs |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
EA201990030A1 (en) | 2016-06-15 | 2019-06-28 | ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи | METHODS AND COMPOSITIONS TO REDUCE OXIDATIVE STRESS |
US20190201350A1 (en) * | 2016-08-15 | 2019-07-04 | Corr-Jensen Inc. | Time release of fat-soluble actives |
CA3077624A1 (en) * | 2016-10-01 | 2018-04-05 | James Smeeding | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
CA3048841A1 (en) | 2016-12-30 | 2018-07-05 | X Traxion, Llc | Extraction of compounds from cannabis |
US10960322B2 (en) | 2018-07-02 | 2021-03-30 | Pratt Bethers | Apparatus for purifying crystals using solvent vapors |
US10308626B1 (en) | 2018-07-02 | 2019-06-04 | Pratt Bethers | Crystal purification in a glass or metal container |
US10561693B2 (en) | 2017-09-01 | 2020-02-18 | MariJ Pharmaceuticals, Inc. | Cultivation, processing, and synthesis of cannabidiols |
EP3453397A1 (en) | 2017-09-12 | 2019-03-13 | Albert Jan Dijkstra | Processes for the isolation of a cannabinoid extract and product from cannabis plant material |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
WO2020041326A1 (en) * | 2018-08-20 | 2020-02-27 | Berkowitz Barry A | Applications of known and novel cannabinoids |
US11026888B1 (en) | 2019-01-04 | 2021-06-08 | Nutrition Therapeutics, Inc. | Functional beverage compositions and methods of using and making same |
US20220106284A1 (en) * | 2019-03-04 | 2022-04-07 | University Of Florida Research Foundation, Inc. | Methods and compositions for substituted axially-chiral cannabinol analogs |
CA3138811A1 (en) | 2019-05-06 | 2020-11-12 | The University Of British Columbia | Antibiotic cannabinoid-terpene formulations |
CA3154135A1 (en) | 2019-09-16 | 2021-03-25 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
GB201916974D0 (en) * | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
WO2021155390A1 (en) * | 2020-01-14 | 2021-08-05 | Shaman Naturals, Llc. | Antimicrobial compositions |
CA3074150A1 (en) | 2020-02-18 | 2021-08-18 | Ovation Science, Inc. | Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc) |
CA3187303A1 (en) | 2020-07-28 | 2022-02-03 | Impello Biosciences, Inc. | Methods and compositions for altering secondary metabolites in plants |
CN112516119A (en) * | 2021-02-05 | 2021-03-19 | 云南维他源生物科技有限公司 | ASBD medicine composition for treating cerebral apoplexy and preparation and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5434295A (en) * | 1994-02-07 | 1995-07-18 | Yissum Research Development Company | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds |
US5521215A (en) * | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US5538993A (en) * | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2304669A (en) | 1940-08-16 | 1942-12-08 | Adams Roger | Isolation of cannabidiol |
US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
IL80411A (en) | 1986-10-24 | 1991-08-16 | Raphael Mechoulam | Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them |
IL92238A (en) * | 1989-11-07 | 1995-07-31 | Yissum Res Dev Co | Nmda blocking composition containing tetrahydro-cannabinol derivatives some novel tetrahydro-cannabinol derivatives and process for their preparation |
US5284867A (en) | 1989-11-07 | 1994-02-08 | Yissum Research Development Company Of The Hebrew University In Jerusalem | NMDA-blocking pharmaceutical compositions |
EP0787492B1 (en) | 1990-03-16 | 2003-09-17 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | Use of nitroxides and oxazolidines for protection against ionising radiation and oxidative stress |
DE4100441A1 (en) | 1991-01-09 | 1992-07-16 | Mack Chem Pharm | PROCESS FOR PREPARING 6,12-DIHYDRO-6-HYDROXY-CANNABIDIOL AND USE THEREOF FOR THE PREPARATION OF TRANS-DELTA-9-TETRAHYDROCANNABINOL |
US5635530A (en) | 1991-09-12 | 1997-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them |
IL99468A (en) | 1991-09-12 | 1997-09-30 | Yissum Res Dev Co | (3s, 4s)-delta- 6-tetrahydrocannabinol- 7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them |
FR2692575B1 (en) | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2713225B1 (en) | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
WO1994012667A1 (en) | 1992-11-27 | 1994-06-09 | The United States Department Of The Army | Inhibitors of arachidonic acid metabolites for preventing neurological damage |
US5696109A (en) | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
CA2102142A1 (en) | 1993-03-30 | 1994-10-01 | Andrew J. Ghio | Method of inhibiting oxidants using alkylaryl polyether alcohol polymers |
FR2714057B1 (en) | 1993-12-17 | 1996-03-08 | Sanofi Elf | New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them. |
ZA958725B (en) | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
IT1271267B (en) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | MONO AND BICARBOXYLIC ACID AMIDES WITH AMINO ALCOHOLS, SELECTIVELY ACTIVE ON THE PERIPHERAL RECEPTOR OF CANNABINOIDS |
FR2741621B1 (en) | 1995-11-23 | 1998-02-13 | Sanofi Sa | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
GB9807639D0 (en) | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
DE69936640D1 (en) * | 1998-04-21 | 2007-09-06 | Us Health | CANNABINOIDS AS ANTIOXIDANTS AND NEUROSHIPPING AGENTS |
-
1999
- 1999-04-21 DE DE69936640T patent/DE69936640D1/en not_active Expired - Lifetime
- 1999-04-21 WO PCT/US1999/008769 patent/WO1999053917A1/en active IP Right Grant
- 1999-04-21 JP JP2000544322A patent/JP2002512188A/en active Pending
- 1999-04-21 US US09/674,028 patent/US6630507B1/en not_active Expired - Lifetime
- 1999-04-21 AU AU38646/99A patent/AU766988B2/en not_active Expired
- 1999-04-21 EP EP99921427A patent/EP1071419B1/en not_active Expired - Lifetime
- 1999-04-21 CA CA002329626A patent/CA2329626A1/en not_active Abandoned
- 1999-04-21 AT AT99921427T patent/ATE367809T1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521215A (en) * | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US5538993A (en) * | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
US5434295A (en) * | 1994-02-07 | 1995-07-18 | Yissum Research Development Company | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds |
Non-Patent Citations (4)
Title |
---|
ESHHAR, N. S. ET AL.: "Neuroprotective and Antioxidant Activities of HU-211, a Novel NMDA Receptor Antagonist", EUR. J. PHARMACOL., vol. 283, no. 1-3, 1995, pages 19 - 29, XP002109752 * |
ESTHER SHOHAMI ET AL.: "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome.", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 17, no. 10, October 1997 (1997-10-01), pages 1007 - 10019, XP002109753 * |
HAMPSON ET AL.: "Cannabidiol and Tetrahhydrocanabinolare neuroprotective antioxidants", PROC. NATL. ACAD. SCI. USA, vol. 95, July 1998 (1998-07-01), pages 8268 - 8273, XP002109751 * |
SKAPER S. D. ET AL.: "The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Neurons", PROC. NATL. ACAD. SCI. USA, vol. 93, 1997, pages 3984 - 3989, XP002109754 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630507B1 (en) * | 1998-04-21 | 2003-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
US20140066497A1 (en) * | 1999-03-22 | 2014-03-06 | Immugen Pharmaceuticals, Inc. | Treatment of immune dysregulation using cannabinoid derivatives |
US6274635B1 (en) | 1999-03-22 | 2001-08-14 | Immugen Pharmaceuticals Inc. | Alkylated resorcinol derivatives for the treatment of immune diseases |
WO2000056303A3 (en) * | 1999-03-22 | 2002-01-24 | Immugen Pharmaceuticals Inc | Treatment of immune diseases |
US9173867B2 (en) * | 1999-03-22 | 2015-11-03 | Immugen Pharmaceuticals, Inc. | Treatment of immune dysregulation using cannabinoid derivatives |
WO2000056303A2 (en) * | 1999-03-22 | 2000-09-28 | Immugen Pharmaceuticals, Inc. | Treatment of immune diseases |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US7105685B2 (en) | 1999-03-22 | 2006-09-12 | Travis Craig R | Cannabinol derivatives |
WO2001003690A1 (en) * | 1999-07-12 | 2001-01-18 | Virginia Commonwealth University | Novel vasodilator cannabinoid analogs |
US6563009B1 (en) | 1999-07-12 | 2003-05-13 | Virginia Commonwealth University | Vasodilator cannabinoid analogs |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
EP2298284A3 (en) * | 2001-02-14 | 2013-12-18 | GW Pharma Limited | Mucoadhesive pharmaceutical formulations |
WO2002064169A1 (en) * | 2001-02-16 | 2002-08-22 | Daiichi Suntory Pharma Co., Ltd. | Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases |
US7598228B2 (en) | 2001-02-16 | 2009-10-06 | Asubio Pharma Co., Ltd. | Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1 |
US10195159B2 (en) * | 2001-05-04 | 2019-02-05 | Gw Pharma Limited | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
US20160038437A1 (en) * | 2001-05-04 | 2016-02-11 | Gw Pharma Limited | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
WO2003015700A2 (en) * | 2001-08-15 | 2003-02-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Novel vasoconstrictor cannabinoid analogs |
US7109245B2 (en) | 2001-08-15 | 2006-09-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vasoconstrictor cannabinoid analogs |
WO2003015700A3 (en) * | 2001-08-15 | 2003-12-18 | Us Gov Health & Human Serv | Novel vasoconstrictor cannabinoid analogs |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
WO2004105699A3 (en) * | 2003-05-28 | 2005-12-15 | Pharmacia Corp | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage |
WO2004105699A2 (en) * | 2003-05-28 | 2004-12-09 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage |
US8071641B2 (en) | 2004-02-16 | 2011-12-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treating or preventing diabetes with cannabidiol |
WO2005077348A1 (en) * | 2004-02-16 | 2005-08-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treating or preventing diabetes with cannabidiol |
WO2006024958A3 (en) * | 2004-08-09 | 2006-12-28 | Novimmune Sa | Cannabinoid compositions and methods of use thereof |
WO2006024958A2 (en) * | 2004-08-09 | 2006-03-09 | Novimmune S.A. | Cannabinoid compositions and methods of use thereof |
WO2007105210A3 (en) * | 2006-03-13 | 2007-11-15 | Hadasit Med Res Service | Therapeutic uses of cannabidiol compounds |
WO2008107879A1 (en) * | 2007-03-05 | 2008-09-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel cannabidiol derivatives and their use as anti-inflammatory agents |
US8293786B2 (en) | 2007-07-30 | 2012-10-23 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
WO2009018389A1 (en) * | 2007-07-30 | 2009-02-05 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
WO2014200350A1 (en) * | 2013-06-13 | 2014-12-18 | Cannabis Science International Holding B.V. | Composition for the treatment of neurobehavioral disorders |
US9763991B2 (en) | 2013-06-13 | 2017-09-19 | Cannabis Science International Holding B.V. | Composition for the treatment of neurobehavioral disorders |
US10413578B2 (en) | 2013-06-13 | 2019-09-17 | Cannabis Science International Holding B.V. | Composition for the treatment of neurobehavioral disorders |
EP3639814A1 (en) * | 2014-06-27 | 2020-04-22 | GW Research Limited | 7-oh-cannabidiol (7-oh-cbd) for use in the treatment of epilepsy |
WO2021007661A1 (en) * | 2019-07-12 | 2021-01-21 | Canopy Growth Corporation | Cannabinoid derivatives |
WO2021245671A1 (en) * | 2020-06-03 | 2021-12-09 | Epm (Ip), Inc. | Cannabidiolic acid (cbda) derivatives and uses thereof |
WO2022017957A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage |
WO2022113071A2 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid derivatives and their use the treatment of inflammation and/or pain and/or obesity |
WO2022113071A3 (en) * | 2020-11-24 | 2022-10-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity |
WO2022238701A1 (en) * | 2021-05-12 | 2022-11-17 | GW Research Limited | Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof |
WO2022238707A1 (en) * | 2021-05-12 | 2022-11-17 | GW Research Limited | Rescorcinols, methods for their manufacture, and uses thereof |
WO2023285072A1 (en) | 2021-07-13 | 2023-01-19 | Receptorpharma Inc S-Corp | Esters of 7-cooh cbd derivatives and their use as prevention, prophylaxis of progression, and/or treatment of neurogenerative diseases. |
CN113735709A (en) * | 2021-09-17 | 2021-12-03 | 中国农业科学院农产品加工研究所 | Cannabidiol-2-butyrate and application thereof |
CN113735709B (en) * | 2021-09-17 | 2022-03-18 | 中国农业科学院农产品加工研究所 | Cannabidiol-2-butyrate and application thereof |
WO2023103734A1 (en) * | 2021-12-10 | 2023-06-15 | 德义制药有限公司 | Cannabidiol derivative, preparation method therefor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2329626A1 (en) | 1999-10-28 |
US6630507B1 (en) | 2003-10-07 |
AU766988B2 (en) | 2003-10-30 |
AU3864699A (en) | 1999-11-08 |
ATE367809T1 (en) | 2007-08-15 |
EP1071419A1 (en) | 2001-01-31 |
DE69936640D1 (en) | 2007-09-06 |
JP2002512188A (en) | 2002-04-23 |
EP1071419B1 (en) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU766988B2 (en) | Cannabinoids as antioxidants and neuroprotectants | |
EP1299374B1 (en) | Novel non-psychotropic cannabinoids | |
US5521215A (en) | NMDA-blocking pharmaceuticals | |
US6096740A (en) | Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions | |
EP1877097B1 (en) | Aminoacid conjugates of beta-lapachone for tumor targeting | |
KR100264348B1 (en) | Pharmaceutical composition containing nebivolol as an anti-atherogenic | |
Sun et al. | A pharmacological review of dicoumarol: An old natural anticoagulant agent | |
JPH11507646A (en) | Synthetic catalytic free radical scavengers useful as antioxidants for disease prevention and treatment | |
JP2003533478A (en) | Method of reducing cell proliferation based on (3R, 4R) -Δ8-tetrahydrocannabinol-11-acid | |
DE60307856T2 (en) | ANTITUMORIC CONNECTION AND ITS THERAPEUTIC USES | |
JP2013082723A (en) | New composition for preventing and treating neurodegenerative and blood coagulation disorders | |
KR101013426B1 (en) | Liposomal delivery of vitamin E based compounds | |
CN113166060A (en) | Treatment of sickle cell disease with pyruvate kinase activating compounds | |
DE602004012279T9 (en) | CATECHOL DERIVATIVES FOR THE TREATMENT OF CANCER | |
Wei et al. | Discovery of coumarin-derived imino sulfonates as a novel class of potential cardioprotective agents | |
US5852052A (en) | Treatment of lyso paf-mediated mental or neuronal disorders with lyso paf or paf antagonists and procedure for determining their efficacy | |
JPH06234756A (en) | Hydroxyamine n-acyl derivative having scavenger activity and being useful for acute and chronic diseases accompanied by hyperoxidation and inflammatory symptom | |
KR950005914B1 (en) | Nmda-blocking pharmaceutical compositions | |
JPH06510280A (en) | Protein kinase C inhibition and the new compound balanol | |
Axelrod et al. | I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111 | |
US5854287A (en) | D-Propranolol metabolites useful for antioxidant activities | |
CA2611860A1 (en) | Compositions and methods of use of derivatized flavanols | |
JP2000510114A (en) | Antioxidant compounds | |
JP4693140B2 (en) | Tocotrienol-containing pharmaceutical agent | |
US20020127287A1 (en) | Treatment of lyso paf-mediated disorders with lyso paf or paf antagonists and procedure for determining their efficacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2329626 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 544322 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 38646/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999921427 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999921427 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09674028 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 38646/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999921427 Country of ref document: EP |